Expression of Survivin in Colorectal Carcinoma and its Clinical Significance_West China Medical Journal

Authors：

YANG Zhou ¹ , GANG Haiju ² , XIE Xianyong ³ ,  ZHANG Caiquan ⁴

1. Department of Gastrointestinal Surgery, Sichuan Academy of Medical Sciences & Sichuan Provincial People′s Hospital, Chengdu, Sichuan 610072, P. R. China; 2. Department of Surgery, 3. Department of Pathology, The Affiliated Hospital, North Sichuan Medical College, Nanchong, Sichuan 637000, P. R. China; 4. Department of General Surgery, the First Affiliated Hospital, Chongqing University of Medical Science, Chongqing 400016, P. R. China;

Corresponding author：

ZHANG Caiquan, Email: cliff_youngz@163.com

Keywords：

Survivin; 结直肠癌; 预后

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

【摘要】　目的　探讨Survivin表达在结直肠癌发生，转移中的作用及临床意义。　方法　 2003年1月－2004年12月间采用免疫组织化学链霉菌抗生物素蛋白-过氧化物酶连结法测定58例结直肠癌、12例结直肠腺瘤和9例正常结肠组织中Survivin的表达水平，研究其与结直肠癌患者临床病理特征及预后的关系。　结果　 Survivin蛋白在正常结直肠黏膜中不表达，而在结直肠腺瘤及结直肠癌组织中的表达均高于正常大肠黏膜，差异有统计学意义（P lt;0.05）。不同年龄、性别、浆膜浸润、淋巴结转移、远处转移、分化程度、Dukes分期等之间Survivin的表达差异均无统计学意义（P gt;0.05）。Kaplan-Meier生存分析提示:Survivin表达阳性患者的5年生存率为51.2%，阴性者为90.9%，两组比较差异有统计学意义（P lt;0.05）。　结论　 Survivin的异常表达参与了结直肠癌发生、发展的病理生理过程，对结直肠癌患者的治疗方式的选择、疗效和预后的评估方面具有重要的参考价值。
【Abstract】　Objective　 To determine the expression of Survivin in the onset and metastasis of colorectal adenocarcinoma, and its clinical significance.　Methods　 From January 2003 to December 2004, immunohistochemical staining, streptavidin-perosidase method, was used to detect the Survivin expression in 58 cases of colorectal carcinoma, 12 cases of colorectal adenoma, and 9 cases of normal tissues. Correlation between the expression of Survivin and clinicopathological factors in colorectal cancer was analyzed.　Results　 Survivin was not expressed in normal colorectal tissues. The expression of Survivin in colorectal carcinoma and adenoma was significantly higher than that in norma1 colorectal tissues (P lt;0.05). There was no correlation of Survivin expression with such clinicopathologic factors as age, gender, serosa infiltration, lymph node metastasis, distal metastasis, differentiation level and Dukes stage (P gt;0.05). The Kaplan-Meier survival analysis demonstrated that patients with Survivin-positive tumors had significantly poorer survival rate (51.2%) than those with Survivin-negative tumors (90.9%) (P lt;0.05).　Conclusion　 Abnormal expression of Survivin plays an important role in carcinogenesis and progress of colorectal carcinoma and can be regarded as a good index for the choice of surgery, and assessment of clinical outcomes and prognosis for colorectal cancer patients.

Citation： YANG Zhou,GANG Haiju,XIE Xianyong,ZHANG Caiquan. Expression of Survivin in Colorectal Carcinoma and its Clinical Significance. West China Medical Journal, 2011, 26(8): 1165-1169. doi: Copy

1.	Altieri DC. Survivin, cancer networks and pathway-directed drug discovery[J]. Nat Rev Cancer, 2008, 8(1): 61-70.
2.	Lam AK, Saleh S, Smith RA, et al. Quantitative analysis of survivin in colorectal adenocarcinoma: increased expression and correlation with telomerase activity[J]. Hum Pathol, 2008, 39(8): 1229-1233.
3.	Ponnelle T, Chapusot C, Martin L, et al. Cellular localisation of survivin: impact on the prognosis in colorectal cancer[J]. J Cancer Res Clin Oncol, 2005, 131(8): 504-510.
4.	Sarela AI, Macadam RC, Farmery SM, et al. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma[J]. Gut, 2000, 46(5): 645-650.
5.	Sarela AI, Scott N, Ramsdale J, et al. Immunohistochemical detection of the anti-apoptosis protein, survivin, predicts survival after curative resection of stage Ⅱ colorectal carcinomas[J]. Ann Surg Oncol, 2001, 8(4): 305-310.
6.	申洪, 陆药丹. 免疫组织化学染色的定量方法研究[J]. 生物医学工程学杂志, 1993, 10(4): 281-284.
7.	Rohayem J, Diestelkoetter P, Weigle B, et al. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients[J]. Cancer Res, 2000, 60(7): 1815-1817.
8.	Zamparese R, Pannone G, Santoro A, et al. Survivin expression in renal cell carcinoma[J]. Cancer Invest, 2008, 26(9): 929-935.
9.	Zaffaroni N, Pennati M, Daidone MG. Survivin as a target for new anticancer interventions[J]. J Cell Mol Med, 2005, 9(2): 360-372.
10.	Altieri DC. The case for survivin as a regulator of microtubule dynamics and cell-death decisions[J]. Curr Opin Cell Biol, 2006, 18(6): 609-615.
11.	Wang CJ, Zhou ZG, Holmqvist A, et al. Survivin expression quantified by Image Pro-Plus compared with visual assessment[J]. Appl Immunohistochem Mol Morphol, 2009, 17(6): 530-535.
12.	Hsiao HL, Wang WS, Chen PM, et al. Overexpression of thymosin beta-4 renders SW480 colon carcinoma cells more resistant to apoptosis triggered by FasL and two topoisomerase Ⅱ inhibitors via downregulating Fas and upregulating Survivin expression, respectively[J]. Carcinogenesis, 2006, 27(5): 936-944.
13.	Knauer SK, Kramer OH, Knosel T, et al. Nuclear export is essential for the tumor-promoting activity of survivin[J]. FASEB J, 2007, 21(1): 207-216.
14.	Falleni M, Pellegrini C, Marchetti A. Survivin gene expression in early-stage non-small cell lung cancer[J]. J Pathol, 2003, 200(5): 620-626.
15.	Qi G, Tuncel H, Aoki E, et al. Intracellular localization of survivin determines biological behavior in colorectal cancer[J]. Oncol Rep, 2009, 22(3): 557-562.
16.	Chen T, Deng C. Inhibitory effect of siRNA targeting survivin in gastric cancer MGC-803 cells[J]. Int Immunopharmacol, 2008, 8(7): 1006-1011.
17.	Carrasco RA, Stamm NB, Marcusson E. Antisense inhibition of survivin expression as a cancer therapeutic[J]. Mol Cancer Ther, 2011, 10(2): 221-232.

1. 　Altieri DC. Survivin, cancer networks and pathway-directed drug discovery[J]. Nat Rev Cancer, 2008, 8(1): 61-70.
2. 　Lam AK, Saleh S, Smith RA, et al. Quantitative analysis of survivin in colorectal adenocarcinoma: increased expression and correlation with telomerase activity[J]. Hum Pathol, 2008, 39(8): 1229-1233.
3. 　Ponnelle T, Chapusot C, Martin L, et al. Cellular localisation of survivin: impact on the prognosis in colorectal cancer[J]. J Cancer Res Clin Oncol, 2005, 131(8): 504-510.
4. 　Sarela AI, Macadam RC, Farmery SM, et al. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma[J]. Gut, 2000, 46(5): 645-650.
5. 　Sarela AI, Scott N, Ramsdale J, et al. Immunohistochemical detection of the anti-apoptosis protein, survivin, predicts survival after curative resection of stage Ⅱ colorectal carcinomas[J]. Ann Surg Oncol, 2001, 8(4): 305-310.
6. 　申洪, 陆药丹. 免疫组织化学染色的定量方法研究[J]. 生物医学工程学杂志, 1993, 10(4): 281-284.
7. 　Rohayem J, Diestelkoetter P, Weigle B, et al. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients[J]. Cancer Res, 2000, 60(7): 1815-1817.
8. 　Zamparese R, Pannone G, Santoro A, et al. Survivin expression in renal cell carcinoma[J]. Cancer Invest, 2008, 26(9): 929-935.
9. 　Zaffaroni N, Pennati M, Daidone MG. Survivin as a target for new anticancer interventions[J]. J Cell Mol Med, 2005, 9(2): 360-372.
10. 　Altieri DC. The case for survivin as a regulator of microtubule dynamics and cell-death decisions[J]. Curr Opin Cell Biol, 2006, 18(6): 609-615.
11. 　Wang CJ, Zhou ZG, Holmqvist A, et al. Survivin expression quantified by Image Pro-Plus compared with visual assessment[J]. Appl Immunohistochem Mol Morphol, 2009, 17(6): 530-535.
12. 　Hsiao HL, Wang WS, Chen PM, et al. Overexpression of thymosin beta-4 renders SW480 colon carcinoma cells more resistant to apoptosis triggered by FasL and two topoisomerase Ⅱ inhibitors via downregulating Fas and upregulating Survivin expression, respectively[J]. Carcinogenesis, 2006, 27(5): 936-944.
13. 　Knauer SK, Kramer OH, Knosel T, et al. Nuclear export is essential for the tumor-promoting activity of survivin[J]. FASEB J, 2007, 21(1): 207-216.
14. 　Falleni M, Pellegrini C, Marchetti A. Survivin gene expression in early-stage non-small cell lung cancer[J]. J Pathol, 2003, 200(5): 620-626.
15. 　Qi G, Tuncel H, Aoki E, et al. Intracellular localization of survivin determines biological behavior in colorectal cancer[J]. Oncol Rep, 2009, 22(3): 557-562.
16. 　Chen T, Deng C. Inhibitory effect of siRNA targeting survivin in gastric cancer MGC-803 cells[J]. Int Immunopharmacol, 2008, 8(7): 1006-1011.
17. 　Carrasco RA, Stamm NB, Marcusson E. Antisense inhibition of survivin expression as a cancer therapeutic[J]. Mol Cancer Ther, 2011, 10(2): 221-232.

West China Medical Journal

Expression of Survivin in Colorectal Carcinoma and its Clinical Significance

Abstract Full text Figures/Tables Video References Cited by

Format

Content